Table 5.
The change in the number of antihypertensive medications for the two groups at baseline and at the 12‐mo post‐procedure follow‐up
| Number of antihypertension medications | Use (%) at Baseline | Use (%) at 6 mo | Use (%) at 12 mo | |||
|---|---|---|---|---|---|---|
| RDN group (n = 30) | Control group (n = 30) | RDN group (n = 28) | Control group (n = 28) | RDN group (n = 28) | Control group (n = 28) | |
| 0 | 0 | 0 | 12 (42.9) | 6 (21.4) | 12 (42.9) | 7 (25.0) |
| 1 | 0 | 0 | 5 (17.5) | 14 (50.0) | 16 (57.1) | 16 (57.1) |
| 2 | 0 | 0 | 11 (39.3) | 6 (21.4) | 0 | 3 (10.7) |
| 3 | 15 (53.6) | 17 (60.7) | 0 | 1 (3.6) | 0 | 2 (7.1) |
| 4 | 10 (35.7) | 11 (39.3) | 0 | 1 (3.6) | 0 | 0 |
| 5 | 3 (10.7) | 0 | 0 | 0 | 0 | 0 |
Data are expressed as N (%).